Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356695 | 0.91 | ADRB3 (0.39) | CYP3A4ADRB3ADRA2BADRA2CIRAK4 | |
| SCHEMBL13617081 | 0.78 | CTSB (0.51) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL13630519 | 0.75 | CYP3A4 (0.45) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL3702245 | 0.75 | BTK (0.32) | — | |
| SCHEMBL6369435 | 0.74 | CTSB (0.44) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL14586235 | 0.74 | CTSB (0.44) | CYP3A4ADRB3ADRA2BADRA2C | |
| SCHEMBL6025399 | 0.74 | CTSB (0.44) | CYP3A4ADRB3ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL2889034 | 0.73 | ADRB3 (0.46) | CYP3A4ADRB3ADRA2BADRA2CIRAK4 | |
| Hydrochloric Acid SCHEMBL2889046 | 0.73 | ADRB3 (0.46) | CYP3A4ADRB3ADRA2BADRA2CIRAK4 | |
| SCHEMBL13617085 | 0.72 | CTSB (0.49) | CYP3A4ADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2283018-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | CYP3A4 379/4885ADRB3 3508/4885ADRA2B 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.